SOUTH SAN FRANCISCO, CA., February 26, 2024 –Maze Therapeutics, a company translating genetic insights into new precision medicines, today announced that company management will participate in upcoming investor conferences in February and March 2024. Details of the events are as follows:

  • Evercore ISI 2024 Emerging Biotech Conference
    • Management will present during the virtual conference on Thursday, February 29, 2024 from 3:25-3:55 p.m. ET
    • The webcast will be available live and on demand here.
  • Cowen Healthcare Conference 2024
    • Management will participate in one-on-one investor meetings on Monday, March 4, 2024
  • Leerink Partners Global Biopharma Conference
    • Management will participate in one-on-one investor meetings on Wednesday, March 13, 2024

 

About Maze Therapeutics

Maze Therapeutics is a biopharmaceutical company harnessing the power of human genetics to transform the lives of patients. The Company is committed to developing breakthrough precision medicines for common diseases with large unmet medical needs. Maze has developed Maze Compass™, a proprietary, purpose-built platform to leverage insights from genetic variation and integrate the critical step of variant functionalization into each stage of therapeutic development. Utilizing Maze Compass, the Company’s strategy is to develop its therapies independently, in collaboration with major pharmaceutical companies, and through company formation. For more information, please visit mazetx.com, or follow us on LinkedIn and X (formerly Twitter).

Contacts:

Jillian Connell, Maze Therapeutics
jconnell@mazetx.com
(650) 850-5080

Media:

Dan Budwick, 1AB
dan@1abmedia.com